{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:21:01Z","timestamp":1787718061521,"version":"build-2784847793"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Comput Aided Mol Des"],"DOI":"10.1007\/s10822-026-00906-2","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T03:58:40Z","timestamp":1787716720000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["In silico discovery of RIOK3 inhibitors against pancreatic ductal adenocarcinoma using homology modelling, molecular docking, molecular dynamics simulations, ADMET prediction, and MTT assay"],"prefix":"10.1007","volume":"40","author":[{"given":"Kawthar","family":"Alhussieni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozana","family":"Othman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamilanban","family":"Thamaraikani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke Han","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malek","family":"Zihlif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha Sura Anak","family":"Lubau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loay","family":"Abujubbeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Alhussieni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vetriselvan","family":"Subramaniyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"906_CR1","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM (2014) Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74:2913\u20132921","journal-title":"Cancer Res"},{"issue":"1","key":"906_CR2","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1186\/s12889-024-17875-6","volume":"24","author":"R He","year":"2024","unstructured":"He R, Jiang W, Wang C, Li X, Zhou W (2024) Global burden of pancreatic cancer attributable to metabolic risks from 1990 to 2019, with projections of mortality to 2030. BMC Public Health 24(1):456","journal-title":"BMC Public Health"},{"issue":"6","key":"906_CR3","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/oncolo\/oyac028","volume":"27","author":"R Elias","year":"2022","unstructured":"Elias R, Cockrum P, Surinach A, Wang S, Chul Chu B, Shahrokni A (2022) Real-world impact of age at diagnosis on treatment patterns and survival outcomes of patients with metastatic pancreatic ductal adenocarcinoma. Oncol 27(6):469\u2013475","journal-title":"Oncol"},{"key":"906_CR4","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.3332\/ecancer.2022.1367","volume":"16","author":"A Ramaswamy","year":"2022","unstructured":"Ramaswamy A, Srinivas S, Chaudhari V, Bhargava P, Bhandare M, Shrikhande SV et al (2022) Systemic therapy in pancreatic ductal adenocarcinomas (PDACs)\u2014basis and current status. Ecancermedicalscience 16:1367","journal-title":"Ecancermedicalscience"},{"issue":"19","key":"906_CR5","doi-asserted-by":"publisher","first-page":"5947","DOI":"10.1021\/acs.jcim.3c01459","volume":"63","author":"A Nunes-Alves","year":"2023","unstructured":"Nunes-Alves A, Merz K (2023) AlphaFold2 in molecular discovery. J Chem Inform Model 63(19):5947\u20135949","journal-title":"J Chem Inform Model"},{"issue":"1","key":"906_CR6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13062-016-0118-5","volume":"11","author":"H Singh","year":"2016","unstructured":"Singh H, Srivastava HK, Raghava GP (2016) A web server for analysis, comparison and prediction of protein ligand binding sites. Biol Direct 11(1):14","journal-title":"Biol Direct"},{"issue":"1","key":"906_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10989-014-9435-7","volume":"21","author":"S Vijayakumar","year":"2015","unstructured":"Vijayakumar S, Ptv L (2015) ACPP: a web server for prediction and design of anti-cancer peptides. Int Pept Res Ther 21(1):99\u2013106","journal-title":"Int Pept Res Ther"},{"issue":"5","key":"906_CR8","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/nprot.2016.051","volume":"11","author":"S Forli","year":"2016","unstructured":"Forli S, Huey R, Pique ME, Sanner MF, Goodsell DS, Olson AJ (2016) Computational protein\u2013ligand docking and virtual drug screening with the AutoDock suite. Nat Protoc 11(5):905\u2013919","journal-title":"Nat Protoc"},{"key":"906_CR9","doi-asserted-by":"publisher","first-page":"20584","DOI":"10.1038\/s41598-020-77602-0","volume":"10","author":"H Puttaswamy","year":"2020","unstructured":"Puttaswamy H, Gowtham HG, Ojha MD, Yadav A, Choudhir G, Raguraman V et al (2020) In silico studies evidenced the role of structurally diverse plant secondary metabolites in reducing SARS-CoV-2 pathogenesis. Sci Rep 10:20584","journal-title":"Sci Rep"},{"key":"906_CR10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/978-3-030-05282-9_5","volume-title":"Structural bioinformatics: applications in preclinical drug discovery process","author":"SK Panday","year":"2019","unstructured":"Panday SK, Ghosh I (2019) In silico structure-based prediction of receptor\u2013ligand binding affinity: current progress and challenges. Structural bioinformatics: applications in preclinical drug discovery process. Springer, pp 109\u2013175"},{"issue":"W1","key":"906_CR11","doi-asserted-by":"publisher","first-page":"W345","DOI":"10.1093\/nar\/gkz424","volume":"47","author":"L Jendele","year":"2019","unstructured":"Jendele L, Krivak R, Skoda P, Novotny M, Hoksza D (2019) PrankWeb: a web server for ligand binding site prediction and visualization. Nucleic Acids Res 47(W1):W345\u2013W349","journal-title":"Nucleic Acids Res"},{"key":"906_CR12","doi-asserted-by":"publisher","first-page":"D1102","DOI":"10.1093\/nar\/gky1033","volume":"47","author":"S Kim","year":"2019","unstructured":"Kim S, Chen J, Cheng T, Gindulyte A, He J, He S et al (2019) PubChem 2019 update: improved access to chemical data. Nucleic Acids Res 47:D1102\u2013D1109","journal-title":"Nucleic Acids Res"},{"key":"906_CR13","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","volume":"7","author":"A Daina","year":"2017","unstructured":"Daina A, Michielin O, Zoete V (2017) SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 7:42717","journal-title":"Sci Rep"},{"key":"906_CR14","doi-asserted-by":"publisher","first-page":"W257","DOI":"10.1093\/nar\/gky318","volume":"46","author":"P Banerjee","year":"2018","unstructured":"Banerjee P, Eckert AO, Schrey AK, Preissner R (2018) ProTox-II: a webserver for the prediction of toxicity of chemicals. Nucleic Acids Res 46:W257\u2013W263","journal-title":"Nucleic Acids Res"},{"key":"906_CR15","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1080\/07391102.2023.2298391","volume":"43","author":"ZA Awan","year":"2025","unstructured":"Awan ZA, Khan HA, Jamal A, Shams S, Zheng G, Wadood A et al (2025) In silico exploration of the potential inhibitory activities of in-house and ZINC database lead compounds against alpha-glucosidase using structure-based virtual screening and molecular dynamics simulation approach. J Biomol Struct Dyn 43:2412\u20132422","journal-title":"J Biomol Struct Dyn"},{"issue":"4","key":"906_CR16","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s11064-025-04520-w","volume":"50","author":"C Wei","year":"2025","unstructured":"Wei C, Heh CH, Lit LC, Chin SP (2025) Comparative molecular dynamics reveals how LRRK2 inhibitors distinguish G2019S from wild-type. Neurochem Res 50(4):259","journal-title":"Neurochem Res"},{"issue":"25","key":"906_CR17","first-page":"3215","volume":"127","author":"MA Anderson","year":"2016","unstructured":"Anderson MA, Deng J, Seymour JF, Tam C, Kim SY, Fein J, Roberts AW (2016) The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood J Am Soc Hematol 127(25):3215\u20133224","journal-title":"Blood J Am Soc Hematol"},{"key":"906_CR18","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/nm.4123","volume":"22","author":"H Jiang","year":"2016","unstructured":"Jiang H, Hegde S, Knolhoff BL, Zhu Y, Herndon JM, Meyer MA et al (2016) Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat Med 22:851\u2013860","journal-title":"Nat Med"},{"key":"906_CR19","doi-asserted-by":"crossref","unstructured":"Schlaepfer DD, Ojalill M, Stupack DG (2024) Focal adhesion kinase signaling\u2013tumor vulnerabilities and clinical opportunities. J Cell Sci 137: jcs261723.","DOI":"10.1242\/jcs.261723"},{"key":"906_CR20","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3389\/fphys.2014.00357","volume":"5","author":"E Rozengurt","year":"2014","unstructured":"Rozengurt E (2014) Mechanistic target of rapamycin (mTOR): a point of convergence in the action of insulin\/IGF-1 and G protein-coupled receptor agonists in pancreatic cancer cells. Front Physiol 5:357","journal-title":"Front Physiol"},{"key":"906_CR21","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1186\/1471-2407-10-368","volume":"10","author":"MM Javle","year":"2010","unstructured":"Javle MM, Shroff RT, Xiong H, Varadhachary GA, Fogelman D, Reddy SA et al (2010) Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer 10:368","journal-title":"BMC Cancer"},{"issue":"4","key":"906_CR22","doi-asserted-by":"publisher","first-page":"680","DOI":"10.3390\/cancers16040680","volume":"16","author":"NK Sharma","year":"2024","unstructured":"Sharma NK, Bahot A, Sekar G, Bansode M, Khunteta K, Sonar PV, Sinha BK (2024) Understanding cancer\u2019s defense against topoisomerase-active drugs: a comprehensive review. Cancers 16(4):680","journal-title":"Cancers"},{"issue":"14","key":"906_CR23","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.3390\/ijms21144919","volume":"21","author":"M Kciuk","year":"2020","unstructured":"Kciuk M, Marciniak B, Kontek R (2020) Irinotecan\u2014still an important player in cancer chemotherapy: a comprehensive overview. Int J Mol Sci 21(14):4919","journal-title":"Int J Mol Sci"},{"issue":"1","key":"906_CR24","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1021\/ci100275a","volume":"51","author":"T Hou","year":"2011","unstructured":"Hou T, Wang J, Li Y, Wang W (2011) Assessing the performance of the MM\/PBSA and MM\/GBSA methods 1 The accuracy of binding free energy calculations based on molecular dynamics simulations. J Chem Model 51(1):69\u201382","journal-title":"J Chem Model"},{"key":"906_CR25","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","volume":"10","author":"S Genheden","year":"2015","unstructured":"Genheden S, Ryde U (2015) The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities. Expert Opin Drug Discov 10:449\u2013461","journal-title":"Expert Opin Drug Discov"},{"issue":"2","key":"906_CR26","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Elmore SW (2013) ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19(2):202\u2013208","journal-title":"Nat Med"},{"key":"906_CR27","unstructured":"Spitz AZ (2020) Identification and characterization of an FDA-approved small molecule inhibitor of pro-apoptotic BAX. Albert Einstein College of Medicine"},{"key":"906_CR28","doi-asserted-by":"publisher","first-page":"S157","DOI":"10.1002\/jcph.706","volume":"56","author":"A Hucke","year":"2016","unstructured":"Hucke A, Ciarimboli G (2016) The role of transporters in the toxicity of chemotherapeutic drugs: focus on transporters for organic cations. J Clin Pharmacol 56:S157\u2013S172","journal-title":"J Clin Pharmacol"},{"key":"906_CR29","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1210\/jc.2005-2287","volume":"91","author":"JK Ghali","year":"2006","unstructured":"Ghali JK, Koren MJ, Taylor JR, Brooks-Asplund E, Fan K, Long WA et al (2006) Efficacy and safety of oral conivaptan: a V1A\/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab 91:2145\u20132152","journal-title":"J Clin Endocrinol Metab"},{"key":"906_CR30","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S0010-7824(96)00195-3","volume":"54","author":"U Fuhrmann","year":"1996","unstructured":"Fuhrmann U, Krattenmacher R, Slater EP, Fritzemeier K-H (1996) The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 54:243\u2013251","journal-title":"Contraception"},{"issue":"15","key":"906_CR31","doi-asserted-by":"publisher","first-page":"5271","DOI":"10.3390\/ijms21155271","volume":"21","author":"R Guennoun","year":"2020","unstructured":"Guennoun R (2020) Progesterone in the brain: hormone, neurosteroid and neuroprotectant. Int J Mol Sci 21(15):5271","journal-title":"Int J Mol Sci"},{"issue":"2","key":"906_CR32","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3390\/biom10020225","volume":"10","author":"MD Spritzer","year":"2020","unstructured":"Spritzer MD, Roy EA (2020) Testosterone and adult neurogenesis. Biomolecules 10(2):225","journal-title":"Biomolecules"},{"key":"906_CR33","unstructured":"VENCLEXTA FDA, Tablets V. (2016) Prescribing information. AbbVie Inc and Genentech USA Inc North Chicago, IL and South San Francisco, CA"},{"key":"906_CR34","first-page":"356","volume":"5","author":"RB Reynolds","year":"2014","unstructured":"Reynolds RB, Folloder J (2014) Clinical management of pancreatic cancer. J Adv Pract Oncol 5:356","journal-title":"J Adv Pract Oncol"},{"key":"906_CR35","doi-asserted-by":"publisher","first-page":"4527","DOI":"10.1158\/1078-0432.CCR-16-0955","volume":"23","author":"AW Roberts","year":"2017","unstructured":"Roberts AW, Stilgenbauer S, Seymour JF, Huang DCS (2017) Venetoclax in patients with previously treated chronic lymphocytic leukemia. Clin Cancer Res 23:4527\u20134533","journal-title":"Clin Cancer Res"},{"issue":"4","key":"906_CR36","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, Seymour JF (2016) Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. New England J Med 374(4):311\u2013322","journal-title":"New England J Med"},{"issue":"8","key":"906_CR37","first-page":"2182","volume":"7","author":"RH Mathijssen","year":"2001","unstructured":"Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A (2001) Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 7(8):2182\u20132194","journal-title":"Clin Cancer Res"},{"key":"906_CR38","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1053\/j.gastro.2018.12.038","volume":"156","author":"VP Balachandran","year":"2019","unstructured":"Balachandran VP, Beatty GL, Dougan SK (2019) Broadening the impact of immunotherapy to pancreatic cancer: challenges and opportunities. Gastroenterology 156:2056\u20132072","journal-title":"Gastroenterology"},{"issue":"19","key":"906_CR39","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouch\u00e9 O, Guimbaud R, B\u00e9couarn Y, Ducreux M (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. New England J Med 364(19):1817\u20131825","journal-title":"New England J Med"},{"key":"906_CR40","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1002\/jcb.20566","volume":"96","author":"RR Singh","year":"2005","unstructured":"Singh RR, Kumar R (2005) Steroid hormone receptor signaling in tumorigenesis. J Cell Biochem 96:490\u2013505","journal-title":"J Cell Biochem"},{"key":"906_CR41","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature16965","volume":"531","author":"P Bailey","year":"2016","unstructured":"Bailey P, Chang DK, Nones K, Johns AL, Patch A-M, Gingras M-C et al (2016) Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531:47\u201352","journal-title":"Nature"}],"container-title":["Journal of Computer-Aided Molecular Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-026-00906-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10822-026-00906-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-026-00906-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T03:58:42Z","timestamp":1787716722000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10822-026-00906-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["906"],"URL":"https:\/\/doi.org\/10.1007\/s10822-026-00906-2","relation":{},"ISSN":["1573-4951"],"issn-type":[{"value":"1573-4951","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"assertion":[{"value":"18 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"214"}}